GENERAL (Narrative) (Details) - USD ($) $ in Thousands |
1 Months Ended | 12 Months Ended | |||||
|---|---|---|---|---|---|---|---|
Aug. 05, 2013 |
Jan. 31, 2024 |
Dec. 31, 2024 |
Dec. 31, 2023 |
Dec. 18, 2023 |
Dec. 31, 2022 |
Nov. 30, 2021 |
|
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||
| Net loss | $ (14,231) | $ (18,754) | $ (33,694) | ||||
| Accumulated deficit | (488,758) | (474,527) | |||||
| Net cash used in operating activities | 49,604 | $ (35,886) | $ (34,113) | ||||
| Non-refundable upfront payment | $ 60,000,000 | ||||||
| Milestone payment | 30,000,000 | ||||||
| Potential milestone compensation company is now eligible for | $ 758,000,000 | ||||||
| Preclinical milestone compensation | $ 23,200 | ||||||
| Amount of investment in Compugen | 12,000 | $ 20,000 | |||||
| Upfront payment received | $ 10,000 | 10,000 | |||||
| Accrued milestone payment | 30,500 | ||||||
| Potential milestone compensation | $ 200,000 | ||||||
| Percentage of expected from payment amount paid | 15.00% | ||||||
| X | ||||||||||
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. No definition available.
|
| X | ||||||||||
- Definition Amount of milestone payment receivables. No definition available.
|
| X | ||||||||||
- Definition Amount of non-refundable upfront payment. No definition available.
|
| X | ||||||||||
- Definition Percentage of expected from payment amount paid. No definition available.
|
| X | ||||||||||
- Definition Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements. No definition available.
|
| X | ||||||||||
- Definition Potential milestone compensation company is now eligible for. No definition available.
|
| X | ||||||||||
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. No definition available.
|
| X | ||||||||||
- Definition Nominal or face amount on the investment owned. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of accumulated undistributed earnings (deficit). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|